Clinical Trial Update: Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase II trial evaluating BI 2536, a PLK-1 inhibitor, in advanced, unresectable pancreatic cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Neoplasms

Drugs mentioned

• BI-2536

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pancreatic Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2022-05-04